Autolus Therapeutics Q4 Earnings Call Highlights

Autolus Therapeutics logo Autolus Therapeutics (NASDAQ:AUTL) executives highlighted a "very good first year of launch" for AUCATZYL during the company's fourth- quarter and full-year 2025 financial results call, pointing to $74.3 million in revenue recognized in 2025, expanded U.S. treatment-center activation, and early real-world outcomes that management said aligned well with prior clinical trial results. Commercial launch update and 2026 outlook Chief Executive Officer Dr. Christian Itin said the company ...